Europe’s Largest Plant for Medical Isotope Products to be Built in Obninsk
On January 20, the groundbreaking ceremony of the first Russian plant for medical isotope products according to GMP standards took place in Obninsk.
Modern pharmaceutical production will be formed by the Rosatom State Corporation at the site of the Research Institute of Physics and Chemistry named after L.Ya. Karpov. It will become the Europe’s largest enterprise to produce the expanded range of radiopharmaceuticals.
The solemn ceremony was attended by Alexei Likhachev, Director General of Rosatom State Corporation, Mikhail Murashko, Minister of Health of the Russian Federation, Vasily Shpak, Deputy Ministry of Industry and Trade of Russia, Vladislav Shapsha, Governor of the Kaluga Region, Andrey Kaprin, Director General of the Federal State Budgetary Institution National Medical Research Center for Radiology of the Russian Ministry of Health.
A wide range of radiopharmaceuticals and active pharmaceutical substances will be produced in Obninsk, including the most popular products based on iodine-131, samarium-153, and molybdenum-99 isotopes. Active radiopharmaceutical substances and drugs based on lutetium-177, actinium-225, radium-223 and other isotopes are to be produced in the future.
By 2025, 21 production lines will make it possible to produce radiopharmaceutical products for the diagnosis and treatment of a wide range of diseases, including inoperable metastatic forms of cancer.
“Nuclear medicine technologies are best methods for diagnosing and treating oncological diseases and cardiovascular diseases. The Europe’s largest radiopharmaceuticals plant was constructed in Russia by Rosatom State Corporation as a timely response to the growing demand for high-tech medical care in Russian healthcare,” Mikhail Murashko said.
“A new high-tech production facility built by Rosatom to produce a wide range of radiopharmaceuticals necessary for Russian doctors and patients is the most important contribution for our country to be technologically sovereign in circulating this category of medicines. In the near future, SPIC 2.0 will be signed between Research Institute of Physics and Chemistry named after L.Ya. Karpov, the Ministry of Industry and Trade of the Russian Federation and the Government of the Kaluga Region. This will allow the company to receive an expanded set of state support measures,” Vasily Shpak explained.
“It is very important that this project is being implemented in Obninsk, because a very serious and effective symbiosis of nuclear industry enterprises, a scientific school and a scientific medical center has developed here, which not only applies radiopharmaceuticals in practice, but also orders to create new drugs to treat specific diseases. Thanks to this mutually beneficial cooperation we can expect that the line of drugs that will be produced at the new plant will rapidly expand,” Vladislav Shapsha noted.